Medical Review (Jun 2024)
Genomic characterization and risk stratification of esophageal squamous dysplasia
- Min Qingjie,
- Zhang Min,
- Lin Dongmei,
- Zhang Weimin,
- Li Xianfeng,
- Zhao Lianmei,
- Teng Huajing,
- He Tao,
- Sun Wei,
- Fan Jiawen,
- Yu Xiying,
- Chen Jie,
- Li Jinting,
- Gao Xiaohan,
- Dong Bin,
- Liu Rui,
- Liu Xuefeng,
- Song Yongmei,
- Cui Yongping,
- Lu Shih-Hsin,
- Li Ruiqiang,
- Guo Mingzhou,
- Wang Yan,
- Zhan Qimin
Affiliations
- Min Qingjie
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Zhang Min
- Novogene Co. Ltd, Beijing, China
- Lin Dongmei
- Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), 12519Peking University Cancer Hospital & Institute, Beijing, China
- Zhang Weimin
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Li Xianfeng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Zhao Lianmei
- Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- Teng Huajing
- Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), 12519Peking University Cancer Hospital & Institute, Beijing, China
- He Tao
- Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China
- Sun Wei
- Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), 12519Peking University Cancer Hospital & Institute, Beijing, China
- Fan Jiawen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Yu Xiying
- Department of Etiology and Carcinogenesis and State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Chen Jie
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Li Jinting
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Gao Xiaohan
- State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Dong Bin
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Central Laboratory, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Liu Rui
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Liu Xuefeng
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning, China
- Song Yongmei
- State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Cui Yongping
- Shenzhen Peking University-The Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
- Lu Shih-Hsin
- Department of Etiology and Carcinogenesis and State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Li Ruiqiang
- Novogene Co. Ltd, Beijing, China
- Guo Mingzhou
- Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China
- Wang Yan
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- Zhan Qimin
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, 12519Peking University Cancer Hospital & Institute, Beijing, China
- DOI
- https://doi.org/10.1515/mr-2024-0008
- Journal volume & issue
-
Vol. 4,
no. 3
pp. 244 – 256
Abstract
The majority of esophageal squamous dysplasia (ESD) patients progress slowly, while a subset of patients can undergo recurrence rapidly or progress to invasive cancer even after proper treatment. However, the molecular mechanisms underlying these clinical observations are still largely unknown.
Keywords
